View
217
Download
0
Category
Tags:
Preview:
Citation preview
Assessment Methodology:
Lessons from
OMERACT Meetings
Vibeke Strand, MDBiopharmaceutical Consultant
Adjunct Clinical Professor, Division of Immunology, Stanford University
OMERACT: Outcome Measures in
Rheumatology Clinical Trials• I: 1992: Rheumatoid Arthritis Clinical Trials
• II: 1994: Adverse Events → Establishment of Registries
Health Related Quality of LifeEconomic Evaluations
• III: 1996: OsteoarthritisOsteoporosisPsychosocial Measures
• IV: 1998: Longitudinal Observational StudiesRA Response Criteria / Imaging Ankylosing Spondylitis → ASASSystemic Lupus Erythematosus
• 5: 2000: MCIDEconomics: Cost EffectivenessImaging: Radiography and MRI
• 6: 2002: Economic EvaluationsImaging
What is OMERACT?
• Data driven process to define outcome measures to be used in RCTs and LOS for each clinical indication
• Domains derived from the “Ds”: DiscomfortDisabilityDollar costDeath
• Literature reviews, data available from LOS and RCTs:
• Validity of currently defined instruments to assess outcome
• “Data mining” to better understand clinical response
• Correlation of patient reported responses with other outcome measures
• Definition of “minimally clinically important improvement”= MCID
What is OMERACT?
• Presentation of evidence and development of consensus at each conference: Representatives from: Academia, Clinical Investigators,
Regulatory Agencies, Sponsors, Clinical Rheumatologists
• Goal: To Develop Recommendations for:
• “Core Set” of minimum number of domains / outcome measures assessed in RCTs and LOS
• Working agenda identifying ‘need’ to focus future work
• Previous OMERACT Recommendations have been ratified by WHO / ILAR in RA, OA, SLE, including HRQOL and
Economic evaluations
The OMERACT ‘Umbrella’
OSTEOARTHRITIS: OARSI
ANKYLOSING SPONDYLITIS: ASAS
PAIN:
IMMPACT
RHEUMATOID ARTHRITIS:EULARACR
JRA:PRCSG
SLE: SLICC EULAR
The OMERACT Filter
• TRUTH: Face, content, construct and criterion validityIs the measure truthful?Does it measure what is intended?
• DISCRIMINATION: Reliability and sensitivity to changeDoes the measure discriminate between situations
[states] of interest?
• FEASIBILITY: Can the outcome easily be measured given
constraints of time, money and interpretability?
Boers et al: JRheum 1998: 25: 198-9
Rheumatoid Arthritis: OMERACT I, 1992
• RCTs available, but data limited• Only a few included a measure of physical function• General ‘belief’ that none had demonstrated convincing
efficacy
• “Paper patients” derived from actual RCT data
• → [healthy] arguments regarding changes reported• Clear disagreement about importance of MD
Global assessments• Participants ranked patient reported physical
function and SJC highest when assessing efficacy
• Facilitated recognition that ‘perception’ of benefit variable
ACR Response CriteriaACR Response Criteria
• Defined and Ratified after OMERACT IData driven nominal group process
• Based on Paulus criteria and statistical analyses of CSSRD and MTX RCTsbest differentiating active therapy from placebo
• Require ≥20% improvement in 5 of 7 measures:
• Tender Joint Count and Swollen Joint Count
• and 3 of the following 5: MD Global Physical function: HAQ
Pain by VASPatient GlobalESR and/or CRP
• Defined and Ratified after OMERACT IData driven nominal group process
• Based on Paulus criteria and statistical analyses of CSSRD and MTX RCTsbest differentiating active therapy from placebo
• Require ≥20% improvement in 5 of 7 measures:
• Tender Joint Count and Swollen Joint Count
• and 3 of the following 5: MD Global Physical function: HAQ
Pain by VASPatient GlobalESR and/or CRP
EULAR Response Definition
>3.2 and ≤5.1
>5.1
≤3.2
DAS28 Score>1.2 ≤0.6>0.6 to ≤1.2
Decrease in DAS28
Good
Moderate
None
Van Gestel et al. Arth Rheum 1996; 26:705-11
DIscriminant function analysis of patients w/active; inactive RADisease activity state determined by treatment changes
As Demonstrated in RA, Responder Analyses
Have Face and Content Validity
As Demonstrated in RA, Responder Analyses
Have Face and Content Validity
• Allow assessment of multiple domains
• Facilitate comparison of efficacy across:• Products• Heterogeneous populations, and• Disease indications
• May lead to tiered approach to label indications
• Precedent: ACR Responder Index in RA DAS28 both confirms active disease
at baseline and ‘clinical responses’ Additional data by x-ray and HRQOL
• Allow assessment of multiple domains
• Facilitate comparison of efficacy across:• Products• Heterogeneous populations, and• Disease indications
• May lead to tiered approach to label indications
• Precedent: ACR Responder Index in RA DAS28 both confirms active disease
at baseline and ‘clinical responses’ Additional data by x-ray and HRQOL
Rheumatoid Arthritis: Later Efforts
• Demonstrated that ‘generic’ measures of HRQOL sensitive to change in RA RCTs
• Identified ‘MCID’ for HAQ and SF-36……facilitating:
• Comparisons across products, disease populations
• Economic evaluations
• Helped to show impact of ‘Rheumatic Diseases’ to WHO
• In this Bone and Joint Decade
• Identified importance of Rheumatic Diseases relative to CV, DM, HTN, OP….
• [Hopefully] → allocation of more resources toidentify and treat Rheumatic Diseases…..
Minimum Clinically Important Differences
[MCID]
Minimum Clinically Important Differences
[MCID]
• Degree of improvement
• Perceptible to patients = clinically important/ meaningful
• Defined by patient query, delphi techniqueOMERACT: 33-36% improvement;18% > placebo
• Confirmed by statistical correlations with patient global assessments in RCTs in RA and OA
• Determination of proportion of patients with clinically important improvement provides a more interpretable result with direct clinical implications
• Degree of improvement
• Perceptible to patients = clinically important/ meaningful
• Defined by patient query, delphi techniqueOMERACT: 33-36% improvement;18% > placebo
• Confirmed by statistical correlations with patient global assessments in RCTs in RA and OA
• Determination of proportion of patients with clinically important improvement provides a more interpretable result with direct clinical implications
1 Guzman et al. Arth Rheum. 1996; 39:5208 2 Kosinski et al. Arth Rheum. 2000; 43:1478-873 Redelmeier et al. Arch Intern Med. 1993; 153:1337-424 Wells et al. J Rheumatol. 1993; 20:557-605 Kosinski et al. Arth Rheum. 2000; 43:S140 6 Samsa et al. Pharmacoeconomics. 1999; 15:141-155 7 Thumboo et al. J Rheumatol. 1999; 26:97-102.
Minimum Clinically Important Differences
[MCID]
HAQ DI 1-4 0 - 3 – 0.22
SF-36 2, 5-7 0 - 100 + 5 - 10 points
PCS/MCS mean 50 ± 10 + 2.5 - 5 points
HAQ DI 1-4 0 - 3 – 0.22
SF-36 2, 5-7 0 - 100 + 5 - 10 points
PCS/MCS mean 50 ± 10 + 2.5 - 5 points
Score Direction MCIDRange of Scoring Literature
Score Direction MCIDRange of Scoring Literature
Health Assessment Questionnaire (HAQ)Health Assessment Questionnaire (HAQ)
• Widely accepted, validated, rheumatology-specific
instrument to assess physical function in RA
• Gold Standard: OMERACT/FDA Guidance
• 20 questions covering 8 types of activities
Dressing + Grooming; Arising; Eating; Walking;
Hygiene; Reaching; Gripping, Activities of Daily Living
• HAQ Disability Index (HAQ DI)
• Scores the worst items within each of the eight scales
• Based on use of aids and devices
• Widely accepted, validated, rheumatology-specific
instrument to assess physical function in RA
• Gold Standard: OMERACT/FDA Guidance
• 20 questions covering 8 types of activities
Dressing + Grooming; Arising; Eating; Walking;
Hygiene; Reaching; Gripping, Activities of Daily Living
• HAQ Disability Index (HAQ DI)
• Scores the worst items within each of the eight scales
• Based on use of aids and devices
Mean Improvement in HAQ Disability Index
Year-2 Cohorts at 24 Months
Improvement
Worsening
Mea
n C
han
ge
fro
m B
asel
ine
LEF MTX
US301 MN302/304
SSZ
MN301/303/305
*LEF vs MTX; p=0.01
-1
-0.5
0
-0.22
-0.73
-0.56
-0.6
-0.37
-0.48 -0.56
*
(248) (273)(51) (46)(97) (101)
% Achieving MCID 84% 69% 86% 82% 74% 78%
ATTRACT: HAQ Disability Index
Mean Improvement through Week 102Mean Improvement through Week 102
MTX + PlaceboMTX + Placebo 3 mg/kgq8w
3 mg/kgq8w
3 mg/kgq4w
3 mg/kgq4w
10 mg/kgq8w
10 mg/kgq8w
10 mg/kgq4w
10 mg/kgq4w
< 0.001< 0.001 < 0.001< 0.001 < 0.001< 0.001 < 0.001< 0.001p-value vs. MTX + Placebop-value vs. MTX + Placebo
0.2
0.4
0.5 0.5
0.40.45
0
0.1
0.2
0.3
0.4
0.5
Allinfliximab
Allinfliximab
Mea
n i
mp
rove
men
tM
ean
im
pro
vem
ent
ERA: Mean Change in HAQ DI at Month 12
-0.80Me
an
Ch
an
ge
fro
m B
L
MTX
ETN
-0.70-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
MCID
Baseline HAQ DI: 1.6 1.6
Kosinski et al. AJMC. 2002;8:231-240
Mean Changes in HAQ DI at Weeks 24 and 52
Anakinra+MTX
-0.18 -0.15
-0.29 -0.28
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
Me
an
Ch
an
ge
fro
m B
ase
line
Placebo+MTX
Anakinra+MTX
24 weeks 52 weeks
MCID
Baseline: 1.38 Placebo 1.43 Active
Fleishman et al. Arth Rheum. 2002;46:S574.
Mean Changes in HAQ DI at Weeks 24 and 52
DE019: Adalimumab+MTX
-0.24 -0.25
-0.6 -0.61-0.56 -0.59
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0.0
Me
an
Ch
an
ge
fro
m B
ase
line
Placebo BL 1.48
Adalimumab 20 mg weekly BL 1.45
Adalimumab 40 mg eow BL 1.44
24 weeks 52 weeks
MCID
Keystone E. Arthritis & Rheum 2002; 46(9) suppl.
Mean Changes in HAQ DI from Weeks 30 to 54
ASPIRE RCT
-0.79-0.75M
ea
n C
ha
ng
e fr
om
BL
; W
ks
30
-54
MTX
MTX+INF 3 mg/kg
MTX+INF 6mg/kg
-0.78
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
MCID
Baseline HAQ DI: 1.5 1.5 1.5
% Achieving MCID: 65 76 76Smolen et al. Ann Rheum Ds 2003;62:S64
Mean Changes in HAQ DI at Weeks 52
TEMPO RCT
-0.97
-0.61
Me
an
Ch
an
ge
fro
m B
L
MTX
ETNMTX+ETN
-0.66
-0.8
-0.7
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
MCID
Baseline HAQ DI: 1.7 1.7 1.8
-0.9
-1.0
SF-36: Short Form 36 Health Survey
• Validated, widely used generic measure of HRQOL• 8 Domains:
• Scored 0 - 100; age, sex adjusted rates• 2 Summary Scores
• Physical Component: PCS– Measures how decrements in physical function
affect day to day activities– Impact of physical impairment/disability on
HRQOL• Mental Component: MCS
– Impact of mental affect, symptoms of pain on HRQOL
• Normative based scoring (Mean: 50, SD: 10)
• Validated, widely used generic measure of HRQOL• 8 Domains:
• Scored 0 - 100; age, sex adjusted rates• 2 Summary Scores
• Physical Component: PCS– Measures how decrements in physical function
affect day to day activities– Impact of physical impairment/disability on
HRQOL• Mental Component: MCS
– Impact of mental affect, symptoms of pain on HRQOL
• Normative based scoring (Mean: 50, SD: 10)
SF-36 Two-Component ModelSF-36 Two-Component Model
PhysicalComponent
MentalComponent
PhysicalFunction
RolePhysical
BodilyPain
GeneralHealth
VitalitySocial
FunctionRole
EmotionMentalHealth
US 301: Baseline SF-36 Scores
US Norms vs US301 Population
US 301: Baseline SF-36 Scores
US Norms vs US301 Population
0PhysicalFunction
RolePhysical
BodilyPain
GeneralHealth
Perception
Vitality SocialFunction
RoleEmotion
MentalHealth
Study US301 PopulationUS Norms (A/S Adjusted)
10
20
30
40
50
60
70
80
90
100
US301: Mean Improvement in SF-36: Year-2
Cohorts Leflunomide and Methotrexate
US301: Mean Improvement in SF-36: Year-2
Cohorts Leflunomide and Methotrexate
BetterBetter
Mea
n S
core
s
Physical Role Bodily General Vitality Social Role MentalFunction Physical Pain Health Function Emotion Health
Perception
Physical Role Bodily General Vitality Social Role MentalFunction Physical Pain Health Function Emotion Health
Perception
0
10
20
30
40
50
60
70
80
90
LEF 24 Months (n = 93)LEF 24 Months (n = 93)
MTX 24 Months (n = 89)MTX 24 Months (n = 89)US Norms (A/S Adjusted)US Norms (A/S Adjusted)
Baseline Year-2 CohortBaseline Year-2 Cohort
35 PlaceboAdalimumab (40 mg) QOW
5.2
13.5
8.2
14.6
28.1
23.3
0
5
10
15
20
25
30
Me
an
Ch
an
ge
Fro
m B
as
elin
e
3.5
8.7 9.0
16.9
7.5
13.4
5.2
15.5
2.3
6.7
Mean Changes in SF-36 Scores
DE019: Adalimumab+MTX
MCID
Vitality
Physical Functio
ning
Physical Role
Bodily Pain
General Health
Social Functio
ning
Emotional H
ealth
Mental Health
Keystone E. Arthritis & Rheum 2002; 46 suppl.
Leflunomide and Methotrexate: Mean
Changes in SF-36 PCS Year-2 Cohort (US301)
60
US Norm
2 SDs below
US Norm
LEF (93) MTX (97)
BL 12 M 24 M BL 12 M 24 M
Impr
oved
Mea
n S
core
s
0
10
20
30
40
50
30.9
42.7 41.7
30.2
38.6 38.8
Etanercept and Methotrexate: Mean Changes
SF-36 PCS at 12 Months (ERA)
60
US Norm
2 SDs below
US Norm
Impr
oved
Mea
n S
core
s
0
10
20
30
40
50
BLBL 12M12M
Kosinski et al. AJMC. 2002;8:231-240.
ETN 25mg (193) MTX (199)
28.0
38.7
29.2
38.8
Infliximab: Median Improvement in SF-36 PCS
at Month 24 (ATTRACT)
Baseline: 23.9 –30.8
Kavanaugh et al. Arth Rheum. 2000;43:S147.
p-value vs. placebo
MTX + Placebo(n=88)
3 mg/kgq 8 wks
(n=86) 0.011
3 mg/kgq 4 wks
(n=86) <0.001
10 mg/kgq 8 wks(n=87)
<0.001
10 mg/kgq 4 wks
(n=81)<0.001
Med
ian
(IQ
R)
0
4
8
12
16
2.8
4.6
6.8 6.9 6.7
Anakinra+MTX: Mean Improvement in SF-36
PCS at Month 12
Baseline: 29.9 PL28.8 Active
Fleishman et al. Arth Rheum. 2002;46:S574.
Correlation Between HAQ and SF-36
Reference Study Scales Correlation
Ruta 1 — PCS -0.77
Talamo 2 — PF -0.72
Kavanaugh 3 Infliximab/ATTRACT PCS -0.51PF -0.54
Kosinski 4 Etanercept/ERA PCS -0.60PF -0.61
Lubeck 5 Etanercept/RAPOLO PCS -0.79PF -0.82
Strand 6 Leflunomide/US301 PCS -0.60PF -0.74
1 Ruta et al. Br J Rheum. 1998;37:425-436.2 Talamo et al. Br J Rheum. 1997;36:463-469.3 Kavanaugh et al. A&R. 2000;43:S147.4 Kosinski et al. Medical Care. 1999;37:MS23-39.5 Lubeck et al. Value in Health. 2001;4:MS2,163.6 Strand et al. A&R. 2001;44:S187.
MCID Values Are Consistent in RCTs in RA
• Improvements in HAQ DI and SF-36 in RA
with newly approved therapies are statistically
significant; more importantly, CLINICALLY
MEANINGFUL
• MCID values are consistent across agents and patient
populations
• Disease specific [‘relevant’] measure: HAQ
• Generic measure: SF-36
• Improvements in disease specific highly correlated
with generic measures
• Improvements in HAQ DI and SF-36 in RA
with newly approved therapies are statistically
significant; more importantly, CLINICALLY
MEANINGFUL
• MCID values are consistent across agents and patient
populations
• Disease specific [‘relevant’] measure: HAQ
• Generic measure: SF-36
• Improvements in disease specific highly correlated
with generic measures
MCID Workshop: Identifying Candidate Measures
to Define ‘Low Disease Activity State’
• Pain
• Function
• Inflammation
• Health Related Quality of life
• Structure damage
• Toxicity
• Co-morbidity
• Fatigue
Osteoarthritis
• OMERACT III: 1996
• Candidate instruments to assess:• Pain• Stiffness• Physical Function
• Limited data from RCTs; treatments offering only symptomatic benefit
• Identification of a ‘Core Set’ of 4 Domains as a foundation for future work
• Research Agenda: Identification of ‘Disease Control’, ‘Biologic Markers’ of Response
Western Ontario and McMaster Universities
(WOMAC) Osteoarthritis Index
• Self-administered questionnaire
• Developed querying patients with hip or knee OA
• Reflects physical activities most affected by symptoms, disease manifestations
• Composite score based on 24 questions; subscores:
• Pain (5 questions)
• Joint stiffness (2 questions)
• Physical function (17 questions)
• Scored by 0 - 4 Likert or 0 - 10 cm VAS scales
• Improvement = negative change
• Self-administered questionnaire
• Developed querying patients with hip or knee OA
• Reflects physical activities most affected by symptoms, disease manifestations
• Composite score based on 24 questions; subscores:
• Pain (5 questions)
• Joint stiffness (2 questions)
• Physical function (17 questions)
• Scored by 0 - 4 Likert or 0 - 10 cm VAS scales
• Improvement = negative change
BIOLOGIC MARKERS
HRQOL / UTILITY
PAINPAINPHYSICAL PHYSICAL FUNCTIONFUNCTION
PATIENT GLOBALPATIENT GLOBALIMAGING (≥1YR)IMAGING (≥1YR)
INFLAM-MATION
Placement Consequence
INNER Core CORE SET
MIDDLE Core HRQOL/ Utility (Strongly Recommended)
OUTER Core OPTIONAL
Placement Consequence
INNER Core CORE SET
MIDDLE Core HRQOL/ Utility (Strongly Recommended)
OUTER Core OPTIONAL
≥ 90%
≥30% - <90%
0% - <30%
≥ 90%
≥30% - <90%
0% - <30%
% Voting for inclusion% Voting for inclusion
8%8%36%36%90%90%
OTHER Eg, Performance based Flares Time to Surgery Analgesic Count
MD GLOBALMD GLOBAL
STIFFNESS
Pain: WOMAC pain / stiffness subscalesDifferentiating pain from stiffness
Physical function: WOMAC physical function subscale
Patient Global Assessment: How to phrase question?Signal jointIn all the ways arthritis affects you, how are you
doing today?Transition question
HRQOL/Utilities: WOMAC Composite ScoreSF-36EQ5D / Utilities
MD Global Assessment
Pain: WOMAC pain / stiffness subscalesDifferentiating pain from stiffness
Physical function: WOMAC physical function subscale
Patient Global Assessment: How to phrase question?Signal jointIn all the ways arthritis affects you, how are you
doing today?Transition question
HRQOL/Utilities: WOMAC Composite ScoreSF-36EQ5D / Utilities
MD Global Assessment
Outcome Measures in OA: OARSI GuidelinesOMERACT Core Set and ‘Strongly Recommended’
WOMAC Scores in OA RCTs: Identifying MCID
• MCID in WOMAC composite score, Likert scale:
• Anchored to Patient Global Assessment
• 12 wk pivotal OA RCTs with Celecoxib: 10.1 [0 – 89]
• Pain, Stiffness, Physical Fxn: 2.1, 1.2, 6.5[0 – 20] [0 – 8] [0 – 61]
• MCID in WOMAC VAS:
• Anchored to Patient Response to Rx [0-4 Likert scale]
• 6 wk RCTs OA hip, knee; Rofecoxib v Ibuprofen v PL:
• Pain, Stiffness, Physical Fxn: 9.7, 10, 9.3 mm, VAS
• 11 mm VAS for Patient Global Assessment
• MCID in WOMAC composite score, Likert scale:
• Anchored to Patient Global Assessment
• 12 wk pivotal OA RCTs with Celecoxib: 10.1 [0 – 89]
• Pain, Stiffness, Physical Fxn: 2.1, 1.2, 6.5[0 – 20] [0 – 8] [0 – 61]
• MCID in WOMAC VAS:
• Anchored to Patient Response to Rx [0-4 Likert scale]
• 6 wk RCTs OA hip, knee; Rofecoxib v Ibuprofen v PL:
• Pain, Stiffness, Physical Fxn: 9.7, 10, 9.3 mm, VAS
• 11 mm VAS for Patient Global Assessment
Ehrich et al: JRheum 2000;27: 2635-2641
Zhao et al. Pharmacother 1999;19:1269-78
0
2
4
6
8
10
12
14
CT20: knee CT21: knee CT54: hip
Placebo Cel 50 Cel 100 Cel 200 Nap 500
Improvement in WOMAC Composite Scores at
Week 12 : Pivotal OA RCTs, Celecoxib
Imp
rove
d S
core
s
* P <.05 v placebo
*
**
*
*
*
*
*
*
*
*
*
MCID = 10.1 (SE=0.4)
Zhao et al Pharmacother 1999;19:1269-78
WOMAC Physical Function Subscale, knee or
hip OA at 12 months: Pivotal RCT, Rofecoxib
R = randomizationP < 0.05 for all groups; treatment response compared with baseline Cannon GW, et al. Arthritis Rheum. 2000;43:978–987.
R = randomizationP < 0.05 for all groups; treatment response compared with baseline Cannon GW, et al. Arthritis Rheum. 2000;43:978–987.
Mea
n C
han
ge
(mm
)M
ean
Ch
ang
e (m
m)
-30-30
-35-35
-25-25
-20-20
-15-15
-10-10
-5-5
00
RR 22 44 88 1212 2626 3939 5252
WeekWeek
Rofecoxib 12.5 mg
Rofecoxib 25 mg
Diclofenac 150 mg
Rofecoxib 12.5 mg
Rofecoxib 25 mg
Diclofenac 150 mg
Mean baseline = 69.6 mmMean baseline = 69.6 mm
MCID = 9.3
SF-36 in Osteoarthritis RCTsSF-36 in Osteoarthritis RCTs• Truth or Validity
• Domains, especially Bodily Pain discriminated differences/ changes in symptoms over time
• Closer correlation with patient assessed outcomes
• Feasibility or Reliability
• Ceiling effects minimal; floor effects for RP and RE domains
• Able to detect effects of arthritis in community sample
• Discrimination or Responsiveness
• In longitudinal tests, BP domain and PCS summary score most responsive, even within 2-6 weeks
• Valid and responsive measure of TKR, esp long term
• Short term treatment → significant improvement in MCS
• Truth or Validity
• Domains, especially Bodily Pain discriminated differences/ changes in symptoms over time
• Closer correlation with patient assessed outcomes
• Feasibility or Reliability
• Ceiling effects minimal; floor effects for RP and RE domains
• Able to detect effects of arthritis in community sample
• Discrimination or Responsiveness
• In longitudinal tests, BP domain and PCS summary score most responsive, even within 2-6 weeks
• Valid and responsive measure of TKR, esp long term
• Short term treatment → significant improvement in MCSBrooks et al, A+R 1997; 40:S110
Ehrich et al: JRheum 2000;27: 2635-2641
Ware et al: A+R 1996; 39:S90
Bellamy et al, A+R 2000; S221
Ware et al: A+R 1996; 39:S90
Hill et al: JRheum 1999; 26:2029-35
0
5
10
15
20
25
US Norms Rofecoxib
PF RP PAIN GHP VITAL SOC RE MH
Mean Improvement in SF-36: All Rofecoxib
v Normative Data US Population
Mean Improvement in SF-36: All Rofecoxib
v Normative Data US Population
Imp
rove
me
nt
Difference between ages 45-54 and 55-64
US population. Ware et al 1993
-1
4
9
14
19
24
PF RP BP GH VT SF RE MH
Placebo Cel 50 Cel 100 Cel 200 Nap 500
Change in SF-36 Scores at Week 12: OA of knee
Pivotal Trial with Celecoxib
*
**
*
**
*
**
* *
*
* * **
*
*
*
* p < .05 v placebo
Use of WOMAC and SF-36 in RCTs of OA
Conclusions Based on the COX-2 Experience
Use of WOMAC and SF-36 in RCTs of OA
Conclusions Based on the COX-2 Experience
• WOMAC Questionnaire reflects clinical improvement consistent with other patient assessed measures
• Proved valid, reliable and sensitive to change• Pain and stiffness subscales reflect symptoms• Physical function subscale dominates composite score• WOMAC Composite score is a disease specific measure
of HRQOL• Correlates closely with improvements reported by
generic SF-36
• Based on MCID calculations, Likert and VAS versions similarly sensitive to change
• WOMAC Questionnaire reflects clinical improvement consistent with other patient assessed measures
• Proved valid, reliable and sensitive to change• Pain and stiffness subscales reflect symptoms• Physical function subscale dominates composite score• WOMAC Composite score is a disease specific measure
of HRQOL• Correlates closely with improvements reported by
generic SF-36
• Based on MCID calculations, Likert and VAS versions similarly sensitive to change
OMERACT 4 SLE Module 1998: Goal
• To develop consensus on required outcome domains
to be assessed in clinical trials in SLE
• Paucity of data from Randomized Controlled Trials [RCTs];
Most evidence derived from Longitudinal Observational
Studies [LOS]
• To develop consensus on required outcome domains
to be assessed in clinical trials in SLE
• Paucity of data from Randomized Controlled Trials [RCTs];
Most evidence derived from Longitudinal Observational
Studies [LOS]
Strand et al: J Rheum 1999; 26: 490-497Smolen et al: J Rheum 1999; 26: 504-507
Disease Activity Indices
BILAG, ECLAM, LAI, SLAM, SLEDAI
• Good evidence for validity, discrimination, feasibility in published cohort [LOS] studies
• Changes in one index correlated with others
• Recommendation to use index of choice– Computer generation of all 5 indices facilitates:
• Clinical research efforts: SLICCESCICITEURO-LUPUS
• Exchange of information: interested partiesbiotech / pharma
• Some limitations when used as primary outcome measures in RCTs; ongoing efforts to improve
• Good evidence for validity, discrimination, feasibility in published cohort [LOS] studies
• Changes in one index correlated with others
• Recommendation to use index of choice– Computer generation of all 5 indices facilitates:
• Clinical research efforts: SLICCESCICITEURO-LUPUS
• Exchange of information: interested partiesbiotech / pharma
• Some limitations when used as primary outcome measures in RCTs; ongoing efforts to improve
• Baseline domain scores low in SLE
– v. age/gender matched norms for Canada, Norway, UK, US
– v. serious medical problems (IDDM, CAD)
• In cohort studies reflects changes in disease activity measures
– disease activity in PF, BP, GHP
– disease activity SF-36 domain scores, esp. PF
• Decrements in multiple domains correlate with increased disease activity and damage
– Immunosuppressive use
– ESRD
• Baseline domain scores low in SLE
– v. age/gender matched norms for Canada, Norway, UK, US
– v. serious medical problems (IDDM, CAD)
• In cohort studies reflects changes in disease activity measures
– disease activity in PF, BP, GHP
– disease activity SF-36 domain scores, esp. PF
• Decrements in multiple domains correlate with increased disease activity and damage
– Immunosuppressive use
– ESRD
SF-36: Sensitive to Change in LOS in SLESF-36: Sensitive to Change in LOS in SLE
Gladman et al: J Rheum 1995; 23:1953-5
Gordon et al: A+R 1997; 40:S112 Gladman et al: Clin Exp Rheum 1995; 14:305-8Stoll et al: J Rheum 1997; 24:309-13 and 1608-14 Fortin et al: Lupus 1998; 7:101-7
Abu-Shakra et al J Rheum 1999; 26:306-9Thumboo et al J Rheum 1999; 26:97-102
Wang et al J Rheum 2001; 28:525-32
Rood et al J Rheum 2000; 27:2057-9
Vu, Escalante J Rheum 1999; 26:2595-2601
Domains Recommended by OMERACT 4
Disease activity: Disease Activity Scores: SLEDAI, BILAG, ECLAM, SELENA SLEDAI, SLAM-R
Definitions of Active Nephritis by U/A, 24 hour CCr,
proteinuria, «Renal flare» «Major SLE Flare»
Damage: ACR/SLICC Damage Index End Stage Renal Disease [ESRD] Doubling of Serum Creatinine Chronicity Index on Biopsy Bone loss due to disease activity and/or corticosteroids
HRQOL: SF-36
[Should also include: Adverse events Economic costs including health utilities]
Disease activity: Disease Activity Scores: SLEDAI, BILAG, ECLAM, SELENA SLEDAI, SLAM-R
Definitions of Active Nephritis by U/A, 24 hour CCr,
proteinuria, «Renal flare» «Major SLE Flare»
Damage: ACR/SLICC Damage Index End Stage Renal Disease [ESRD] Doubling of Serum Creatinine Chronicity Index on Biopsy Bone loss due to disease activity and/or corticosteroids
HRQOL: SF-36
[Should also include: Adverse events Economic costs including health utilities]As reviewed in Schiffenbauer et al: EBM Treatment of SLE; BJR: in press
Ankylosing Spondylitis: ASAS
• A successful and relevant example
• To be discussed by Robert LandeweJuergen Braun
Systemic Sclerosis Workshop: OMERACT 6
Absence of data: Few ‘failed’ RCTs
Limited information from LOS
Assessment by organ system involvement
• Renal
• Cardio-pulmonary
• Muscle
• HRQOL
• Skin
• GI
OMERACT 7
May 12-16, 2004 Asilomar, California
• Module: RA: Definition of Low Disease Activity
• Module Updates:
Imaging in Ankylosing Spondylitis [ASAS]
Working Group on Safety
• Workshops:
Outcome Measures in Psoriatic Arthritis
Outcome Measures in Fibromyalgia
Outcome Measures in Gout
The Patient Perspective in Outcome Measures
Recommended